Pleural Involvement Upon Relapse of Myeloma Responding to Daratumumab Plus Carfilzomib: A Case Presentation and Literature Review

Clin Lymphoma Myeloma Leuk. 2021 Mar;21(3):e267-e271. doi: 10.1016/j.clml.2020.11.017. Epub 2020 Nov 30.

Authors

Atilla Uslu¹, Güldane Cengiz Seval¹, Mustafa Merter¹, Klara Dalva¹, Meral Beksaç²

Affiliations

¹ Hematology Department, Ankara University School of Medicine, Ankara, Turkey.
² Hematology Department, Ankara University School of Medicine, Ankara, Turkey. Electronic address: beksac@medicine.ankara.edu.tr.

PMID: 33380380
DOI: 10.1016/j.clml.2020.11.017

No abstract available

Keywords: Carfilzomib; Daratumumab; Extramedullary plasmacytoma; Flow cytometry; Pleural infiltration.

Publication types

Case Reports
Review

MeSH terms

Aged
Antibodies, Monoclonal / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Disease Management
Humans
Immunophenotyping
Male
Multiple Myeloma / diagnostic imaging
Multiple Myeloma / pathology*
Oligopeptides / administration & dosage
Pleural Neoplasms / diagnosis
Pleural Neoplasms / drug therapy*
Pleural Neoplasms / secondary*
Positron Emission Tomography Computed Tomography
Radiography, Thoracic
Tomography, X-Ray Computed
Treatment Outcome

Substances

Antibodies, Monoclonal
Oligopeptides
daratumumab
carfilzomib